Silver Jubilee for the Frankel Cardiovascular Center: Celebrating the past, present and future
In September, the Frankel CVC celebrated its 25th anniversary. The Center was formally established by the University of Michigan Board of Regents in fall 2000, unifying existing cardiovascular services, research and training programs across the medical campus.
For 25 years, patients from across the state and country have come to Ann Arbor seeking experienced clinicians to diagnose, manage and treat cardiovascular conditions in a
CLINICAL
2025 BY THE NUMBERS
231,434 non-invasive tests (EKG, DVU and echo studies)
99,108 clinic visits
47,325 cardiovascular radiologic exams
5,235 cardiac catheterization cases
3,550 OR cases (cardiac and vascular)
2,966 arrhythmia cases
97.5%
Frankel CVC Clinics
Overall Rating of Care
*Frankel CVC Fiscal Year 2025: July 1, 2024 through June 30, 2025.
The clinical data included in this report reflects activity at University of Michigan Health Frankel Cardiovascular Center in Ann Arbor, not any other owned or affiliated sites across the state.
Standing Together in Cardiovascular Care
compassionate, patient-centered environment. Since its inception, faculty and staff at the Frankel CVC have achieved significant milestones in clinical care, research, education and innovation, all within a mission of advancing medicine and serving humanity.
To celebrate the center’s jubilee, we are sharing 25 milestones from over the years to illustrate the breadth of impact our faculty and staff have had on patients who rely on our expertise.
Our patients have access to the newest treatment options, some of which include:
• DETOUR and LimFlow procedures for patients with advanced peripheral arterial disease.
• The GORE® EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE) implant for patients with thoracoabdominal aortic aneurysms.
• DurAVR, a novel transcatheter heart valve for patients with aortic valve disease, along with other advanced options for percutaneous replacement or repair of the mitral and tricuspid valves.
• Coronary sinus reducer, or Shockwave Reducer, through the COSIRA-II clinical trial for patients with refractory angina — chest pain that persists despite standard treatments and when revascularization (like stents or bypass surgery) isn’t an option.
• Leadless endocardial pacing for patients with cardiac resynchronization therapy.
• Barostimulation device therapy for patients with heart failure.
• Renal denervation for refractory hypertension.
FEATURED PROGRAMS
Adult Congenital Heart Disease (ACHD) Program
Our ACHD Program — the first in Michigan to be accredited as a Comprehensive Care Center by the Adult Congenital Heart Association — is grounded in over 30 years of combined clinical expertise and continues to grow rapidly providing the highest quality care for patients with ACHD.
MI-AORTA Program
The MI-AORTA Program was established with generous donor support and plays a key role in advancing and expanding our highly regarded aortic disease clinical practice, training and research efforts. Through this support, it helps fuel the growth of a world-renowned comprehensive aortic program that treats conditions across the aorta — from valve to aortic bifurcation — using both open and endovascular techniques.
Located adjacent to the Frankel Cardiovascular Center, the D. Dan and Betty Kahn Health Care Pavilion at University of Michigan Health opened in November 2025. The 12-story facility features 264 private rooms capable of converting to intensive care, 20 state-of-the-art operating rooms, three interventional radiology suites, advanced imaging and high-level, specialty care services. It significantly enhances our capacity to accept transfers for complex services, including advanced heart failure and shock.
